Century Therapeutics Announces First Patient Dosed in First-In-Human Phase 1 ELiPSE-1 Trial…
<!-- Name:DistributionId Value:8744827 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->
<!-- Name:IcbCode Value:4570 -->…
Browsing Tag
Century Therapeutics
Century Therapeutics Receives Study May Proceed Notification from FDA for CNTY-101, the First…
– Investigational New Drug Application for CNTY-101, a CAR-iNK product candidate targeting CD19 for B-cell malignancies, cleared by FDA – – First cell product candidate engineered with six precision gene edits including a CD19-CAR,…
Century Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Updates
- Following the recent submission of the IND application for CNTY-101 and pending FDA clearance, the Phase 1 ELiPSE-1 trial in relapsed/refractory lymphoma is on track to commence in the second half of 2022 - - Ended second…
Century Therapeutics Announces Its Addition to the Russell Microcap® Index
PHILADELPHIA, June 24, 2022 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced that it…
Century Therapeutics to Present at the LifeSci Partners 2nd Annual Genetic Medicines Symposium
PHILADELPHIA, June 21, 2022 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced that Lalo…
Century Therapeutics to Present at Upcoming Investor Conferences
PHILADELPHIA, May 03, 2022 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced that…
Century Therapeutics to Present at the ASGCT 25th Annual Meeting
PHILADELPHIA, May 02, 2022 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced that…
Century Therapeutics to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference
PHILADELPHIA, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced that…
Century Therapeutics Announces Its Addition to the Russell 2000® Index
PHILADELPHIA, Sept. 17, 2021 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced that it…